Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Phathom Pharmaceuticals (PHAT) Depreciation and Depletion (2022 - 2023)

Phathom Pharmaceuticals (PHAT) has disclosed Depreciation and Depletion for 2 consecutive years, with $100000.0 as the latest value for Q3 2023.

For Q3 2023, Depreciation and Depletion fell 50.0% year-over-year to $100000.0; the TTM value through Sep 2023 reached $400000.0, changed N/A, while the annual FY2022 figure was $600000.0, 20.0% up from the prior year.
Depreciation and Depletion hit $100000.0 in Q3 2023 for Phathom Pharmaceuticals, roughly flat from $100000.0 in the prior quarter.
Across five years, Depreciation and Depletion topped out at $200000.0 in Q3 2022 and bottomed at $100000.0 in Q1 2022.